These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26002512)

  • 1. Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics.
    Lebon D; Vergez F; Bertoli S; Harrivel V; De Botton S; Micol JB; Marolleau JP; Récher C
    Leuk Res; 2015 Aug; 39(8):818-21. PubMed ID: 26002512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival.
    Ihlow J; Gross S; Sick A; Schneider T; Flörcken A; Burmeister T; Türkmen S; Arnold R; Dörken B; Westermann J
    Leuk Lymphoma; 2019 Jan; 60(1):69-77. PubMed ID: 29846127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
    Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.
    Bertoli S; Paubelle E; Bérard E; Saland E; Thomas X; Tavitian S; Larcher MV; Vergez F; Delabesse E; Sarry A; Huguet F; Larrue C; Bosc C; Farge T; Sarry JE; Michallet M; Récher C
    Eur J Haematol; 2019 Feb; 102(2):131-142. PubMed ID: 30325535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).
    Iriyama N; Hatta Y; Takeuchi J; Ogawa Y; Ohtake S; Sakura T; Mitani K; Ishida F; Takahashi M; Maeda T; Izumi T; Sakamaki H; Miyawaki S; Honda S; Miyazaki Y; Taki T; Taniwaki M; Naoe T
    Leuk Res; 2013 Sep; 37(9):1021-6. PubMed ID: 23810283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and laboratory studies of 17 patients with acute myeloid leukemia harboring t(7;11)(p15;p15) translocation.
    Wei S; Wang S; Qiu S; Qi J; Mi Y; Lin D; Zhou C; Liu B; Li W; Wang Y; Wang M; Wang J
    Leuk Res; 2013 Sep; 37(9):1010-5. PubMed ID: 23800796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cytogenetic model predicts relapse risk and survival in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation in morphologic complete remission.
    Rashidi A; Cashen AF
    Leuk Res; 2015 Jan; 39(1):77-81. PubMed ID: 25481050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics.
    Lee HS; Lee JH; Hur EH; Lee MJ; Lee JH; Kim DY; Kim SH; Seol M; Kang SI; Ryu SG; Kang YA; Lee YS; Kang MJ; Seo EJ; Kim YS; Chi HS; Park CJ; Jang S; Yun SC; Lee KH
    Leuk Res; 2009 Mar; 33(3):426-33. PubMed ID: 18760837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
    Marcucci G; Mrózek K; Ruppert AS; Archer KJ; Pettenati MJ; Heerema NA; Carroll AJ; Koduru PR; Kolitz JE; Sterling LJ; Edwards CG; Anastasi J; Larson RA; Bloomfield CD
    J Clin Oncol; 2004 Jun; 22(12):2410-8. PubMed ID: 15197203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
    Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
    Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study.
    Tachibana T; Andou T; Tanaka M; Ito S; Miyazaki T; Ishii Y; Ogusa E; Koharazawa H; Takahashi H; Motohashi K; Aoki J; Nakajima Y; Matsumoto K; Hagihara M; Hashimoto C; Taguchi J; Fujimaki K; Fujita H; Fujisawa S; Kanamori H; Nakajima H;
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):415-421. PubMed ID: 29673622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
    Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
    Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term survival results according to cytogenetic risk in patients with acute myeloid leukemia--singl center experience].
    Piatkowska-Jakubas B; Mensah-Glanowska P; Salamańczuk Z; Skotnicki AB
    Przegl Lek; 2011; 68(6):291-5. PubMed ID: 22039664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of cytogenetics for venous thromboembolism in acute myeloid leukaemia.
    Lee YG; Kim I; Kwon JH; Yoon SS; Park S; Song L; Yoon JH; Shin SH; Min WS; Kim HJ
    Thromb Haemost; 2015 Jan; 113(1):201-8. PubMed ID: 25339605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.